Neoplasias hematológicas

Teresa Bernal del Castillo

• Médico adjunto, Servicio de Hematología y Hemoterapia HUCA.
• Profesora Asociada, Universidad de Oviedo.

1. Tratamiento de soporte en pacientes sometidos a procedimientos de quimioterapia intensiva, TPH y fármacos hipometilantes.
2. Estratificación pronóstica de las neoplasias mieloides.
3. Desarrollo y aplicación de nuevos fármacos.
4. Efectividad de los tratamientos disponibles para neoplasias hematológicas: fase clínica y preclínica.

• Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology.. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leuk Lymphoma. 2017 Jan;58(1):145-152.
• Amado-Rodríguez L, Bernal T, López-Alonso I, Blázquez-Prieto J, García-Prieto E, Albaiceta GM. Impact of Initial Ventilatory Strategy in Hematological Patients With Acute Respiratory Failure: A Systematic Review and Meta-Analysis. Crit Care Med. 2016 Jul;44(7):1406-13.
• Osorio FG, Soria-Valles C, Santiago-Fernández O, Bernal T, Mittelbrunn M, Colado E, Rodríguez F, Bonzon-Kulichenko E, Vázquez J, Porta-de-la-Riva M, Cerón J, Fueyo A, Li J, Green AR, Freije JM, López-Otín C. Loss of the proteostasis factor AIRAPL causes myeloid transformation by deregulating IGF-1 signaling. Nat Med. 2016 Jan;22(1):91-6.
• Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E; PETHEMA Group, Spanish Society of Hematology.. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016 Feb;41:12-20.
• Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. Eur J Haematol. 2016 Jul;97(1):33-8.
• Kelleher N, Gallardo D, González-Campos J, Hernández-Rivas JM, Montesinos P, Sarrá J, Gil C, Barba P, Guàrdia R, Brunet S, Bernal T, Martínez MP, Abella E, Bermúdez A, Sánchez-Delgado M, Antònia C, Gayoso J, Calbacho M, Ribera JM; Pethema Group, Spanish Society of Hematology.. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. Leuk Lymphoma. 2016;57(1):86-91.
• Falantes J, Delgado RG, Calderón-Cabrera C, Márquez-Malaver FJ, Valcarcel D, de Miguel D, Bailén A, Bargay J, Bernal T, González-Porras JR, Tormo M, Ramos F, Andreu R, Xicoy B, Nomdedeu B, Brunet S, Sánchez J, Jurado AF, Bonanad S, Pérez-Simón JA, Sanz G; Spanish Group of Myelodysplastic Syndromes (GESMD). Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score. Leuk Res. 2015 Jan;39(1):52-7.
• Díez Campelo M, Sánchez-Barba M, de Soria VG, Martino R, Sanz G, Insunza A, Bernal T, Duarte R, Amigo ML, Xicoy B, Tormo M, Iniesta F, Bailén A, Benlloch L, Córdoba I, López-Villar O, Del Cañizo MC; Spanish Registry of MDS.. Results of allogeneic stem cell transplantation in the Spanish MDS registry: prognostic factors for low risk patients. Leuk Res. 2014 Oct;38(10):1199-206.
• Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, González-Campos J, Fernández-Abellán P, Tormo M, Bethencourt C, Brunet S, Hernández-Rivas JM, Moreno MJ, Sarrà J, Del Potro E, Barba P, Bernal T, Grande C, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology.. Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Cancer. 2014 Dec 15;120(24):3958-64.
• Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; Grupo Español de Linfomas y Trasplante Autologo de Médula Ósea (GELTAMO).. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Jul;99(7):e126.
• Bernal T, Diez-Campelo M, Godoy V, Rojas S, Colado E, Alcoceba M, González M, Vidriales B, Sánchez-Guijo FM, López-Corral L, Luño E, del Cañizo C. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome. Leuk Res. 2014 May;38(5):551-6.
• Bernal T, Pardavila EV, Bonastre J, Jarque I, Borges M, Bargay J, Ayestarán JI, Insausti J, Marcos P, González-Sanz V, Martínez-Camblor P, Albaiceta GM. Survival of hematological patients after discharge from the intensive care unit: a prospective observational study. Crit Care. 2013 Dec 30;17(6):R302.
• Briones J, Novelli S, García-Marco JA, Tomás JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernández M, González-Barca E, López D, Caballero D; GELTAMO.. Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica. 2014 Mar;99(3):505-10.
• Xicoy B, Jiménez MJ, García O, Bargay J, Martínez-Robles V, Brunet S, Arilla MJ, Pérez de Oteyza J, Andreu R, Casaño FJ, Cervero CJ, Bailén A, Díez M, González B, Vicente AI, Pedro C, Bernal T, Luño E, Cedena MT, Palomera L, Simiele A, Calvo JM, Marco V, Gómez E, Gómez M, Gallardo D, Muñoz J, de Paz R, Grau J, Ribera JM, Benlloch LE, Sanz G. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma. 2014 Jun;55(6):1300-3.
• Ribera JM, García O, Grande C, Esteve J, Oriol A, Bergua J, González-Campos J, Vall-Llovera F, Tormo M, Hernández-Rivas JM, García D, Brunet S, Alonso N, Barba P, Miralles P, Llorente A, Montesinos P, Moreno MJ, Hernández-Rivas JÁ, Bernal T. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013 May 1;119(9):1660-8.
• Urdinguio RG, Fernandez AF, Moncada-Pazos A, Huidobro C, Rodriguez RM, Ferrero C, Martinez-Camblor P, Obaya AJ, Bernal T, Parra-Blanco A, Rodrigo L, Santacana M, Matias-Guiu X, Soldevilla B, Dominguez G, Bonilla F, Cal S, Lopez-Otin C, Fraga MF. Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res. 2013 Jan 1;73(1):395-405.
• Bernal T, Moncada-Pazos A, Soria-Valles C, Gutiérrez-Fernández A. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia. Exp Hematol. 2013 Feb;41(2):172-9.
• Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016 Apr 28;127(17):2122-30.
• Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015 Oct 22;526(7574):519-24.
• Paiva B, Chandia M, Vidriales MB, Colado E, Caballero-Velázquez T, Escalante F, Garcia de Coca A, Montes MC, Garcia-Sanz R, Ocio EM, Mateos MV, San Miguel JF. Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma. Blood. 2014 Aug 21;124(8):1300-03.
• Ocio EM, Dávila J, Caballero JC, Alonso S, de la Calle VG, García-Sanz R, Gazi L, Opio S, Jiménez M, San-Miguel JF, Mateos MV. Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma. Haematologica. 2015 Jul;100(7):e289-91.

Impacto de azacitidina sobre major Tratamiento de soporte y Tratamiento estándar en pacientes con SMD-intermedio 2 y alto en pràctica clínica habitual.

• Investigador/a principal: Teresa Bernal del Castillo
• Sociedad Española de Hematología y Hemoterapia-Grupo Español de Síndromes Mielodisplásicos (2014-2015)

• TRC 112121. Estudio  fase 3, multicéntrico, aleatorizado, doble ciego, controlado con Placebo de ELTROMBOPAG o placebo en combinación con azacitidina  en sujetos con Síndromes Mielodisplásicos de riesgo intermedio-2 o alto según el IPSS. Código EUDRACT 2013-000918-37
• A phase 3, double-blind, randomized study to compare the efficacy and safety ofluspatercept (ACE-536) versus placebo for the treatment of anemia due to ipss-r very low, low, or intermediate risk myelodysplastic syndromes in subjects with ring sideroblasts who require red blood cell transfusions. Código EUDRACT 2015-003454-41
• SGI-110-04. A phase 3, multicenter, open-label, randomized study of SGI-110 versus treatment choice (TC) in adults with previously untreated acute myeloid leukemia (AML) who are not considered candidates for intensive remission induction chemotherapy. Código EUDRACT 2014-001233-89
• CC-486-AML-001. Código Eudract NCT01757535.A phase 3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid leukemia in complete remission. Código EUDRACT 2014-001233-89
• AZA-AML-001. Código Eudract NCT01074047. A Phase 3, Multicenter, Randomized, Open-label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
• 04-21. Código Eudract NCT01241500. A Phase III, Multi-Center, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine
• SINTRA-REV. Código Eudract NCT01243476. Estudio, multicéntrico, aleatorizado, doble ciego, fase III de Revlimid (Lenalidomida) versus placebo en pacientes con Síndrome Mielodisplasico de bajo riesgo (IPSS bajo e intermedio-1) con alteración en 5q- y anemia sin necesidades transfusionales